Kapoose Creek Bio, a biotechnology firm well-versed in AI-driven natural product drug discovery, has made a significant leap forward with its latest acquisition. The company has secured an exclusive license to the chemical informatics platform of Adapsyn Bioscience and acquired Adapsyn's drug
In the fast-evolving field of cellular biology, fluorescence imaging has emerged as a revolutionary tool for tracking cellular processes. With its ability to provide detailed and dynamic views of life on a microscopic scale, it has opened new paths for research and understanding, profoundly
Switzerland has established itself as a global leader in the biotech industry, making significant advancements in areas such as cancer treatment, immunotherapy, gene and cell therapy, and more. With a strong focus on personalized and precision medicine, the Swiss biotech sector thrives on
Rentschler Biopharma, a globally recognized Contract Development and Manufacturing Organization (CDMO), is making significant strides in the biomanufacturing landscape. The company's recent investments showcase its commitment to expanding cGMP capabilities and bolstering cell and gene therapy
Avandra, the largest federated network for de-identified medical image data, has emerged from stealth mode with a mission to transform how medical imaging is used for research and innovation. With the colossal task of harnessing over two trillion medical images worldwide, Avandra aims to build a
Thermo Fisher Scientific has made a groundbreaking leap in precision medicine with the introduction of the Orbitrap Astral mass spectrometer. This cutting-edge technology ushers in a new era of proteomics and clinical research, fundamentally transforming our approach to precision medicine. Bridging
In recent years, the pharmaceutical and biotechnology sectors have experienced a dynamic landscape in mergers and acquisitions (M&A). From major multimillion-dollar deals to strategic acquisitions targeting high-demand therapeutic areas, the industry has witnessed fluctuations driven by various
AbbVie, renowned for its portfolio of groundbreaking treatments, has achieved a major milestone with the FDA's approval of Vyalev, a novel combination therapy aimed at providing extended movement control for patients with advanced Parkinson’s disease. The approval represents more than just a
Monoclonal antibodies (mAbs) have become a cornerstone of modern medicine, offering targeted therapies for a range of diseases, including various cancers, autoimmune disorders, and infectious diseases. However, developing these complex molecules is resource-intensive, requiring significant time and
The biopharmaceutical industry is undergoing a significant transformation, driven by the need for speed, safety, and cost-efficiency in therapeutic production. The advent of new modalities like cell and gene therapies has added layers of complexity to the already intricate production pipelines. As
